Tecnológico de Monterrey and the Translational Institute of Genomic Singularity (ITRASIG) inaugurated the Genomic and Clinical Innovation Unit in Mexico City, aiming to advance public health diagnostics. The facility will focus on precision medicine and high-throughput genetic analysis.
Cecilia Bañuelos, Head of Innovation, Ministry of Economy, says that the unit is designed to convert scientific knowledge into actionable products: “It is necessary to transform knowledge into value-added products and create a transdisciplinary platform to address problems beyond the laboratory.”
The facility can process up to 14,000 genetic tests per day and aims to develop a national platform for genetic analysis to enhance early responses to viral, bacterial, and fungal outbreaks. Initial projects include a portable platform to measure HIV-1 and CMV viral load at point-of-care for low-infrastructure communities, a molecular tool to replace traditional Gram staining with faster, culture-free detection of Gram-positive and Gram-negative infections, and an AI-based molecular platform for comprehensive sepsis diagnosis.
Located within the Distrito de Innovación Tlalpan, the new unit aims to serve as a national reference point for clinical and genomic innovation. The initiative combines government, academic, and private-sector collaboration to support research, technology development, and precision medicine. The unit’s first phase includes equipment donated by ITRASIG for the diagnosis and treatment of HIV, Gram infections, and sepsis.
The unit is expected to later provide portable genetic diagnostics through the NanoLuci platform, a high-precision, low-cost PCR laboratory, combined with Pablo A.I., a Mexican-developed AI tool focused on human health. These technologies aim to facilitate integration into hospitals, clinics, and community settings, improving access to timely diagnostics in both routine and emergency contexts.